The Vattikuti Urology Institute has performed more robotic procedures than any other hospital in the world. Surgeons at the Institute developed the Vattikuti Institute Prostatectomy, and were the first in the world to perform the procedure on an outpatient.Visit: http://www.drmanimenon.com
Genre: How-to
by: Dr_Menon
Dr. Menon is a pioneer in the development of the robotic prostatectomy, a procedure which enables prostate cancer patients to return to an active and fulfilling life.Visit : www.drmanimenon.com
Rusty Barefoot, Sr. and Larnold Jernigan, Sr. made a valiant attempt at starring in the Spanner commercial. While it was truly an epic fail, we think it made a great web video.http://www.thespanner.comFollow us on Twitter!http://twitter.com/rhettmchttp://twitter.com/linklamontJoin the Kommunity!http://rhettandlinkommunity.com-- Distributed by Tubemogul.
Genre: Funny Videos
by: rhettandlink
As one of the first medical centers in the Northwest to perform robot-assisted surgery, Swedish Medical Center is home to the fastest-growing and most experienced robot-assisted surgical program in the region. Swedish established the multidisciplinary robot-assisted surgical program in 2005 and has since performed more than 2,000 robot-assisted surgeries, more than any other program in the region.http://www.prnewswire.com/mnr/swedish/39951/
Genre: Entertainment
by: comments
One-Time Injectable Drug Enters Final Stage Clinical Trials A new drug developed by Nymox Pharmaceutical may offer doctors a breakthrough in the treatment of a common affliction of men, an enlarged prostate or BPH (benign prostatic hyperplasia). The drug, a novel protein called NX-1207, is entering Phase 3 clinical trials, the last stage before applying for FDA approval. If approved, the drug could offer new hope for the millions of men suffering from BPH. NX-1207 takes a new approach and is injected directly into the zone of the prostate most affected by BPH. Once in the prostate, the drug causes local prostate cell loss where it counts. The procedure takes only a few minutes to perform in a urologist’s office and involves little or no pain or discomfort. There is a need for a new and effective treatment for BPH. The currently approved drugs have undesirable side effects such as dizziness or impaired sexual function. Many men stop taking them because of side effects and generally ...
by: newsinfusion
For more info on this and other stories, visit www.newsinfusion.com Corona, CA, January 27, 2009 – Watson Pharmaceuticals, Inc. (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has approved GELNIQUE™ (oxybutynin chloride) Gel 10%, the first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency. The U.S. OAB market currently exceeds $1.8 billion annually and continues to grow each year. GELNIQUE will provide OAB patients with an effective and novel alternative to currently available oral treatment options. Because the active ingredient in GELNIQUE is delivered transdermally, it is not metabolized by the liver in the same way as orally administered oxybutynin. This results in a low level of side effects, such as dry mouth and constipation. GELNIQUE will be actively marketed to physicians, and Watson anticipates that the ...
